Eli Lilly lung-cancer drug meets goal of Phase III study

Eli Lilly's (LLY +4%) Ramucirumab met the main goal of a Phase III study of patients with second-line non-small cell lung cancer (NSCLC) by improving survival rates compared with a placebo.

Ramucirumab and the placebo were administered in combination with the chemotherapy Docetaxel.

Ramucirumab also showed a statistically significant improvement in progression-free survival. (PR)

From other sites
Comments (2)
  • Momintn
    , contributor
    Comments (6086) | Send Message
    The progression-free survival was less than 2 months in gastric cancer. What is it for this treatment in lung cancer?
    19 Feb 2014, 09:13 AM Reply Like
  • Running Loose
    , contributor
    Comments (15) | Send Message
    Very good point , need to be very astute with them.
    20 Feb 2014, 11:09 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs